CMS (00867) announced that its subsidiary, Demai Pharmaceutical Co., Ltd. ("Demai Pharma," an innovative pharmaceutical company specializing in dermatological health that is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited), received approval from the National Medical Products Administration (NMPA) of China on January 30, 2026, for the New Drug Application (NDA) of Ruxolitinib Phosphate Cream (for the vitiligo indication). The product is intended for the treatment of non-segmental vitiligo with facial involvement in patients 12 years of age and older, representing the first and only targeted drug approved in China for vitiligo treatment, thereby addressing a significant unmet clinical need.